AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27567144 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention (<12 h)
Number of subjects: 542
Study 27567144 — intervention group
Group type: COMPARATOR
Intervention: Late intervention (>48 h)
Number of subjects: 542
Study 27567144 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall TSTE patients
Number of subjects: 542
Study 27567144 — intervention group
Group type: COMPARATOR
Intervention: Overall non-TSTE patients
Number of subjects: 542
Study 27567144 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall TSTE patients (2-year follow-up)
Number of subjects: 542
Study 27567144 — intervention group
Group type: COMPARATOR
Intervention: Overall non-TSTE patients (2-year follow-up)
Number of subjects: 542
Study 27567144 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention (2-year follow-up)
Number of subjects: 542
Study 27567144 — intervention group
Group type: COMPARATOR
Intervention: Late intervention (2-year follow-up)
Number of subjects: 542
Study 24327590 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention (medication reconciliation and patient education)
Number of subjects: 61
Study 24327590 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 61
Study 24327590 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention
Number of subjects: 61
Study 22264669 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 rTMS sessions delivered at 1 Hz to the right dorsolateral prefrontal cortex (DLPRC)
Number of subjects: 20
Study 22264669 — intervention group
Group type: COMPARATOR
Intervention: 10 sham rTMS sessions to the same area
Number of subjects: 20
Study 20662955 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (up to 11 home and telephone contacts over 16 weeks)
Number of subjects: 272
Study 20662955 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 272
Study 20662955 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 272
Study 20662955 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 272
Study 18356697 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil therapy (15 mg/day; n = 26)
Number of subjects: 53
Study 18356697 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 27)
Number of subjects: 53
Study 15976964 — intervention group
Group type: EXPERIMENTAL
Intervention: INR self-management
Number of subjects: 2951
Study 15976964 — intervention group
Group type: COMPARATOR
Intervention: Conventional INR management
Number of subjects: 2951
Study 11588506 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breast feeding
Number of subjects: 272
Study 11588506 — intervention group
Group type: COMPARATOR
Intervention: Breast milk plus other foods
Number of subjects: 272
Study 11588506 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected infants
Number of subjects: 272
Study 11588506 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding mode
Number of subjects: 272
Study 9735589 — intervention group
Group type: EXPERIMENTAL
Intervention: Random assignment to day-hospital or inpatient rehabilitation
Number of subjects: 0
Study 9735589 — intervention group
Group type: COMPARATOR
Intervention: Nonrandom assignment (self-selected treatment)
Number of subjects: 0
Study 7903962 — intervention group
Group type: EXPERIMENTAL
Intervention: c-erb B-2 overexpression
Number of subjects: 107
Study 7903962 — intervention group
Group type: EXPERIMENTAL
Intervention: c-erb B-2 positivity
Number of subjects: 107
Study 7903962 — intervention group
Group type: EXPERIMENTAL
Intervention: c-erb B-2 expression
Number of subjects: 107
Study 2567896 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide
Number of subjects: 12
Study 21126827 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 198
Study 21126827 — intervention group
Group type: COMPARATOR
Intervention: Personalized feedback only (FO)
Number of subjects: 198
Study 89951 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% nitrous oxide
Number of subjects: 9
Study 89951 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% nitrous oxide
Number of subjects: 9
Study 89951 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% nitrous oxide
Number of subjects: 9
Study 89951 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% nitrous oxide
Number of subjects: 9
Study 89951 — intervention group
Group type: EXPERIMENTAL
Intervention: All concentrations of nitrous oxide
Number of subjects: 9
Study 31905885 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher pasta consumption
Number of subjects: 2562
Study 31905885 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasta consumption
Number of subjects: 2562
Study 28910328 — intervention group
Group type: EXPERIMENTAL
Intervention: CARE enhanced program
Number of subjects: 942
Study 28910328 — intervention group
Group type: COMPARATOR
Intervention: Standard government nutrition and health package
Number of subjects: 942
Study 26575248 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavage with normal saline containing adrenaline [1:500,000], n = 30
Number of subjects: 60
Study 26575248 — intervention group
Group type: COMPARATOR
Intervention: Lavage with normal saline only, n = 30
Number of subjects: 60
Study 23972865 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation techniques and back massage
Number of subjects: 60
Study 23972865 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 21146300 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation of the right M1 (10Hz, 80% motor threshold intensity, 1500 pulses per session)
Number of subjects: 36
Study 21146300 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation of the right DLPFC (10Hz, 80% motor threshold intensity, 1500 pulses per session)
Number of subjects: 36
Study 21146300 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 36
Study 20081798 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavinton therapy
Number of subjects: 50
Study 17574705 — intervention group
Group type: EXPERIMENTAL
Intervention: Soup preload (broth and vegetables served separately, chunky vegetable soup, chunky‐pureed vegetable soup, or pureed vegetable soup)
Number of subjects: 60
Study 17574705 — intervention group
Group type: COMPARATOR
Intervention: No preload (control group)
Number of subjects: 60
Study 14760806 — intervention group
Group type: EXPERIMENTAL
Intervention: hylan G-F 20
Number of subjects: 215
Study 14760806 — intervention group
Group type: COMPARATOR
Intervention: triamcinolone hexacetonide
Number of subjects: 215
Study 11394463 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbreaks at 20 min intervals
Number of subjects: 0
Study 11394463 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbreaks at 40 min intervals
Number of subjects: 0
Study 11394463 — intervention group
Group type: COMPARATOR
Intervention: Microbreaks at own discretion (control)
Number of subjects: 0
Study 11394463 — intervention group
Group type: COMPARATOR
Intervention: No breaks
Number of subjects: 0
Study 9893736 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral L-arginine (7 g twice daily)
Number of subjects: 7
Study 9893736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 8281847 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 250 mg four times a day
Number of subjects: 0
Study 8281847 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 500 mg four times a day
Number of subjects: 0
Study 8281847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2525337 — intervention group
Group type: EXPERIMENTAL
Intervention: danazol, 800 mg/day (n = 10)
Number of subjects: 53
Study 2525337 — intervention group
Group type: EXPERIMENTAL
Intervention: danazol, 600 mg/day (n = 8)
Number of subjects: 53
Study 2525337 — intervention group
Group type: EXPERIMENTAL
Intervention: intranasal nafarelin acetate, 800 micrograms/day (n = 10)
Number of subjects: 53
Study 2525337 — intervention group
Group type: EXPERIMENTAL
Intervention: intranasal nafarelin acetate, 400 micrograms/day (n = 25)
Number of subjects: 53
Study 31198103 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriflunomide 14 mg
Number of subjects: 0
Study 31357999 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality incentive payments for general practices, including financial incentives for longer consultations, same day access, and timely follow-up after hospitalization.
Number of subjects: 36
Study 31357999 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality incentive payments for general practices
Number of subjects: 36
Study 31357999 — intervention group
Group type: COMPARATOR
Intervention: Usual care provided by control practices
Number of subjects: 36
Study 27885472 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior cervical discectomy and fusion (ACDF)
Number of subjects: 34
Study 27885472 — intervention group
Group type: COMPARATOR
Intervention: Plate-only open-door laminoplasty
Number of subjects: 34
Study 27885472 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ACDF and laminoplasty
Number of subjects: 34
Study 25807927 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone immediate-release (IR) tablets
Number of subjects: 0
Study 25807927 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone extended-release (ER) tablets
Number of subjects: 0
Study 25807927 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone IR and ER tablets (fed condition)
Number of subjects: 0
Study 25807927 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone-3-glucoside
Number of subjects: 0
Study 25807927 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone tablets (both IR and ER)
Number of subjects: 0
Study 24048387 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 40 mg/day plus quetiapine 300 to 600 mg/day
Number of subjects: 41
Study 24048387 — intervention group
Group type: COMPARATOR
Intervention: Citalopram 40 mg/day plus placebo
Number of subjects: 41
Study 21822077 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (0.5 mg/kg)
Number of subjects: 84
Study 21822077 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.5 mg/kg) and Hydroxyzine (1 mg/kg)
Number of subjects: 84
Study 19672787 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable fat emulsion (Fabuless)
Number of subjects: 15
Study 19672787 — intervention group
Group type: COMPARATOR
Intervention: Milk fat in yoghurt (control)
Number of subjects: 15
Study 17896496 — intervention group
Group type: COMPARATOR
Intervention: Group A: Parol and written notice about the content of root canal treatment
Number of subjects: 360
Study 17896496 — intervention group
Group type: COMPARATOR
Intervention: Group B: Written notice and psychological communication
Number of subjects: 360
Study 17896496 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: Written notice, psychological communication, and local anesthesia
Number of subjects: 360
Study 15472200 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment for 16 weeks
Number of subjects: 12
Study 15472200 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 matched controls)
Number of subjects: 12
Study 15472200 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated FCHL
Number of subjects: 12
Study 15472200 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 12
Study 11678837 — intervention group
Group type: COMPARATOR
Intervention: Four-track abdominal site (standard)
Number of subjects: 96
Study 11678837 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip site
Number of subjects: 96
Study 11678837 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-track abdomen site
Number of subjects: 96
Study 11678837 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-track hip site
Number of subjects: 96
Study 11678837 — intervention group
Group type: EXPERIMENTAL
Intervention: All sites
Number of subjects: 96
Study 9688432 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 18
Study 9688432 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 18
Study 7993812 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation (ABMT) with involved marrow infusion
Number of subjects: 67
Study 7993812 — intervention group
Group type: COMPARATOR
Intervention: Control group (not infused with involved marrow)
Number of subjects: 67
Study 2917115 — intervention group
Group type: EXPERIMENTAL
Intervention: extradural 0.5% bupivacaine hydrochloride 0.75 mg kg‐1
Number of subjects: 144
Study 2917115 — intervention group
Group type: COMPARATOR
Intervention: extradural 0.1% methadone hydrochloride 4 mg after bupivacaine
Number of subjects: 144
Study 2917115 — intervention group
Group type: EXPERIMENTAL
Intervention: continuous extradural infusion of methadone 0.3 mg h‐1 after operation
Number of subjects: 144
Study 4584150 — intervention group
Group type: EXPERIMENTAL
Intervention: THC 3 μg/kg
Number of subjects: 8
Study 4584150 — intervention group
Group type: EXPERIMENTAL
Intervention: THC 6 μg/kg
Number of subjects: 8
Study 4584150 — intervention group
Group type: EXPERIMENTAL
Intervention: THC 9 μg/kg
Number of subjects: 8
Study 4584150 — intervention group
Group type: COMPARATOR
Intervention: Control (0 μg/kg THC)
Number of subjects: 8
Study 4584150 — intervention group
Group type: EXPERIMENTAL
Intervention: THC doses (3, 6, 9 μg/kg)
Number of subjects: 8
Study 31967375 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-blocking (BB) glasses worn from 18:00 to 08:00 for seven consecutive nights
Number of subjects: 20
Study 31967375 — intervention group
Group type: COMPARATOR
Intervention: Placebo (clear glasses) worn from 18:00 to 08:00 for seven consecutive nights
Number of subjects: 20
Study 31967375 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-blocking (BB) glasses
Number of subjects: 20
Study 30553120 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconditional cash transfers with guidance from women's group facilitators and community members
Number of subjects: 22
Study 27813240 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labour
Number of subjects: 425
Study 27813240 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 425
Study 25874530 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 166
Study 25874530 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 166
Study 25874530 — intervention group
Group type: EXPERIMENTAL
Intervention: Both risperidone and olanzapine
Number of subjects: 166
Study 23684901 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month weight loss intervention emphasizing reduced energy intake and portion-controlled menu suggestions
Number of subjects: 95
Study 23684901 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month weight loss intervention
Number of subjects: 95
Study 23684901 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed control group
Number of subjects: 95
Study 21078702 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise and general practitioner (GP) care group received 12 supervised exercise sessions at baseline and four booster sessions one year later.
Number of subjects: 120
Study 21078702 — intervention group
Group type: COMPARATOR
Intervention: Standard GP care (Control group)
Number of subjects: 120
Study 19900653 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 5674
Study 16772624 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (2 g/d)
Number of subjects: 546
Study 16772624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 546
Study 15009708 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet-radiation (UVR) exposure at 1 minimal erythema dose (MED)
Number of subjects: 22
Study 15009708 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet-radiation (UVR) exposure (0, 0.6, 1, or 2 MED)
Number of subjects: 22
Study 15009708 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet-radiation (UVR) exposure
Number of subjects: 22
Study 15009708 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinitrochlorobenzene sensitization
Number of subjects: 22
Study 11360127 — intervention group
Group type: EXPERIMENTAL
Intervention: ispaghula husk
Number of subjects: 10
Study 11360127 — intervention group
Group type: EXPERIMENTAL
Intervention: guar gum
Number of subjects: 10
Study 9243379 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafast MP-RAGE sequence (TR = 5.8, TE = 2.9, TI = 20; imaging time, 15 seconds)
Number of subjects: 50
Study 9243379 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafast three-dimensional gradient-echo sequence (TR = 8.2, TE = 3; imaging time, 18 seconds)
Number of subjects: 50
Study 9243379 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard fast three-dimensional gradient-echo sequence (TR = 15, TE = 6; imaging time, 32 seconds)
Number of subjects: 50
Study 9243379 — intervention group
Group type: COMPARATOR
Intervention: Conventional angiography
Number of subjects: 50
Study 8374940 — intervention group
Group type: EXPERIMENTAL
Intervention: Gn-RH analogue (leuprolide)
Number of subjects: 30
Study 8374940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 3526790 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine salicylate 2 mg
Number of subjects: 60
Study 3526790 — intervention group
Group type: COMPARATOR
Intervention: Pethidine chloride 50 mg
Number of subjects: 60
Study 3526790 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 60
Study 3526790 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study 29935544 — intervention group
Group type: EXPERIMENTAL
Intervention: Baicalin 500 mg orally every day for 12 weeks
Number of subjects: 374
Study 29935544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 374
Study 26638878 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated foot orthoses
Number of subjects: 102
Study 26638878 — intervention group
Group type: COMPARATOR
Intervention: Rocker‐sole footwear
Number of subjects: 102
Study 25125229 — intervention group
Group type: EXPERIMENTAL
Intervention: Newcastle infant dialysis and ultrafiltration system (Nidus)
Number of subjects: 10
Study 25125229 — intervention group
Group type: COMPARATOR
Intervention: Peritoneal dialysis (PD)
Number of subjects: 10
Study 25125229 — intervention group
Group type: COMPARATOR
Intervention: Conventional haemodialysis (HD)
Number of subjects: 10
Study 22322522 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold lateral compaction of gutta‐percha (LC)
Number of subjects: 204
Study 22322522 — intervention group
Group type: EXPERIMENTAL
Intervention: Backfill ‐ Thermafil obturation technique (BT)
Number of subjects: 204
Study 22322522 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermafil technique (TT)
Number of subjects: 204
Study 20869187 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care with structured counseling
Number of subjects: 0
Study 20869187 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 17522841 — intervention group
Group type: EXPERIMENTAL
Intervention: Practical and mental training
Number of subjects: 36
Study 17522841 — intervention group
Group type: COMPARATOR
Intervention: Practical training
Number of subjects: 36
Study 15758628 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-side (R)
Number of subjects: 90
Study 15758628 — intervention group
Group type: COMPARATOR
Intervention: Combination (C)
Number of subjects: 90
Study 15758628 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine (S)
Number of subjects: 90
Study 12227400 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ambulatory peritoneal dialysis (CAPD) patients
Number of subjects: 24
Study 12227400 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 24
Study 12227400 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPD patients
Number of subjects: 24
Study 10525709 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 5 mg/day
Number of subjects: 210
Study 10525709 — intervention group
Group type: COMPARATOR
Intervention: Alfacalcidol 1 microgram/day
Number of subjects: 210
Study 7600430 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E treatment
Number of subjects: 22
Study 7600430 — intervention group
Group type: COMPARATOR
Intervention: No vitamin E treatment
Number of subjects: 22
Study 7600430 — intervention group
Group type: COMPARATOR
Intervention: Healthy control
Number of subjects: 22
Study 1292438 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric treatment (PT)
Number of subjects: 72
Study 1292438 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal behavioural therapy (MBT)
Number of subjects: 72
Study 1292438 — intervention group
Group type: COMPARATOR
Intervention: Both PT and MBT
Number of subjects: 72
Study 6442711 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin 6 mg daily and placebo injection
Number of subjects: 24
Study 6442711 — intervention group
Group type: COMPARATOR
Intervention: Sodium aurothiomalate 50 mg monthly and placebo tablets
Number of subjects: 24
Study 6442711 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (Auranofin and Sodium aurothiomalate)
Number of subjects: 24
Study 30457162 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 134
Study 29848769 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants
Number of subjects: 10000
Study 29848769 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin or warfarin
Number of subjects: 10000
Study 27695980 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental fatigue plus caffeine ingestion (5 mg/kg) (MF-CAF)
Number of subjects: 8
Study 27695980 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental fatigue plus placebo (MF-PLA)
Number of subjects: 8
Study 27695980 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 8
Study 27695980 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental fatigue (MF)
Number of subjects: 8
Study 25894953 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive edivoxetine (12-18 mg/day)
Number of subjects: 1249
Study 25894953 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive edivoxetine
Number of subjects: 1249
Study 25894953 — intervention group
Group type: COMPARATOR
Intervention: Adjunctive placebo
Number of subjects: 1249
Study 22941038 — intervention group
Group type: EXPERIMENTAL
Intervention: MGN-3
Number of subjects: 48